f-star Biotechnologische Forschungs-und Entwicklungsges.m.b.H, an antibody engineering company based in Vienna, Austria and Cambridge, UK, has closed an €8m extended Series A financing.
The round was co-led by MP Healthcare Venture Management (MPH) and Merck Serono Ventures, with participation from existing investors Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital.
The company, which develops therapeutic antibodies and antibody fragments based on its “Modular Antibody Technology”, will use the funds to support drug discovery and development efforts.
Dr Kevin FitzGerald, CEO of the company, was reported as saying: “This investment, coupled with a rapidly maturing technology and highly committed management and staff, provides a solid platform on which f-star can create novel medicines and grow significant value”.
FinSMEs
06/01/2010